3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
11
Lung Neoplasms
5
Lymphoma, Large-Cell, Anaplastic
2
Brain Neoplasms
2
Sexual Dysfunction, Physiological
1
Neuroma, Acoustic
1
Neurofibromatosis 2
1
Neoplasm Metastasis
1
NSCLC
1
Meningioma
1
Granuloma, Plasma Cell
1
Gastrointestinal Neoplasms
1
Eunuchism
1
Erectile Dysfunction
1
Ependymoma
1
Disease Progression
1
Carcinoma, Pancreatic Ductal
1
Carcinoma
1
Breast Neoplasms
1
Interventions
Radiosurgery
6
Bevacizumab
4
Gentamicins
3
Everolimus
3
Cochlear Implants
3
Lapatinib
2
tozuleristide
1
neratinib
1
icotinib
1
gallium Ga 68 dotatate
1
brigatinib
1
Triamcinolone Acetonide
1
Sufentanil
1
Sirolimus
1
Microsurgery
1
Methylprednisolone
1
Magnetic Resonance Spectroscopy
1
Losartan
1
Head Movements
1
HDAC-42
1
Fluoresceins
1
Fluorescein
1
Exome
1
Endostatins
1
Endoscopes
1
Docosahexaenoic Acids
1
Decision Support Techniques
1
Axitinib
1
Aspirin
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neuroma, Acoustic
×
brigatinib
×
Clear all
NCT04374305
2026-05-06
INTUITT-NF2
Massachusetts General Hospital
Phase 2
Recruiting
109 enrolled